



Note: Doses are for adults; for use in children please refer to the children's BNF. (See BNF for more information on all drug therapies).

## The Duration of Treatment should correspond to the period of allergenic exposure.

If a person has uncontrolled symptoms following initial self-management strategies and drug treatment, consider stepping up treatment:

- If there is persistent watery rhinorrhoea despite combined use of an intranasal corticosteroid and oral antihistamine, add in an intranasal anticholinergic such as ipratropium bromide.
- If there is persistent **nasal itching** and sneezing, options are to add in a **non-sedating oral antihistamine** to be used regularly rather than 'as needed'.
- If the person has ongoing symptoms and a history of **asthma**, consider adding in a leukotriene receptor antagonist such as **montelukast** to an oral or intranasal antihistamine.
- Nasal congestion: Add in a short-term intranasal decongestant such as ephedrine (OTC) or xylometazoline (OTC) for up to 5 to 7 days, depending on the person's age and preparation used.
- If the person has severe, uncontrolled symptoms that are significantly affecting quality of life, consider prescribing a short course of oral corticosteroids to provide rapid symptom relief, such as:
  - $\circ$  ~ For adults: prednisolone 0.5mg/kg in the morning for 5 to 10 days.
  - $\circ$   $\,$  For children: prednisolone 10 to 15 mg in the morning for 3 to 7 days.



•

## Allergic Rhinitis Pathway



References: NICE CKS Allergic Rhinitis August 2021, BSACI Guideline for the diagnosis and management of allergic and non-allergic rhinitis (2017)

Version	<ul> <li>2.0 Harmonisation of Hertfordshire Medicines Management Committee (HMMC) guidance and West Essex Medicines</li> <li>Optimisation Programme Board (WEMOPB) guidance updates include:         <ul> <li>Rebadging with HWE ICB and removal of ENHCCG and HVCCG headers</li> <li>Review date removed and replaced with standard statement.</li> </ul> </li> </ul>
Developed by	Acknowledgments to West Essex CCG, produced by ENHCCG and HVCCG PMOT
Approved by	HMMC
Date approved/updated	March 2022
Review date:	The recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available.
Superseded version	1.0 Links to CCG repaired